Germany advises against Moderna jab for under-30s

Germany advises against Moderna jab for under-30s


Credit: Unsplash/CC0 Public Domain

German health authorities on Wednesday advised against the use of the Moderna coronavirus vaccine for people under 30 due to evidence of a small risk of cardiac inflammation.

The Stiko commission cited studies showing that mRNA jabs led in rare cases to the conditions myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) in , with slightly higher prevalence in those who received Moderna.

“For people above the age of 30 there is no higher ,” it added.

As a result, the Stiko updated its coronavirus vaccine guidance and “recommends that people under 30 only be vaccinated with Comirnaty,” the BioNTech-Pfizer jab, one day after France issued similar guidance.

The advisory covers both initial inoculations and booster jabs even if the first vaccine was Moderna, it added.

The Stiko bases its recommendations on the findings of Germany’s Federal Institute for Vaccines and Biomedicines, which compiles data on side effects and complications.

The US has also delayed approval of the Moderna jab for young people, though last week they recommended use of the Pfizer vaccine for children ages five to 11 after reviewing the risks of myocarditis.

Paediatric cardiologist Matthew Oster, commenting on the Pfizer recommendation at the time, said he was “much more worried” about the risks of COVID to than risks posed by the vaccine.


France advises against Moderna for under-30s over rare heart risk


© 2021 AFP

Citation:
Germany advises against Moderna jab for under-30s (2021, November 10)
retrieved 10 November 2021
from https://medicalxpress.com/news/2021-11-germany-moderna-jab-under-30s.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Leave a Reply